ROCKVILLE, Md. and SHANGHAI, China, Oct. 16,
2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the
"Company"), a global biotechnology company focused on bringing
highly differentiated medicines to patients around the world
through the discovery, development, and commercialization of novel
immunotherapies and biologics, today announced that the updated
clinical results from its Phase 1 study of givastomig (also known
as TJ-CD4B/ABL111) in advanced solid tumors will be reported in a
poster presentation at the upcoming European Society for Medical
Oncology (ESMO) Congress 2023, on Monday,
October 23 at 12:00 p.m.
CET.
Presentation details:
Abstract
Title:
|
First-In-Human Phase
I Study of Givastomig, A Novel Claudin 18.2/4-1BB Bispecific
Antibody in Advanced Solid Tumors
|
Presentation
Number:
|
1039P
|
Presenter:
|
Dr. Geoffrey Ku,
Memorial Sloan Kettering Cancer Center
|
Session:
|
Poster Presentation:
Investigational
Immunotherapy
|
Location:
|
Hall 8, IFEMA Madrid,
Spain
|
Presentation
Date/Time:
|
Monday, October 23,
2023, 12:00 p.m. – 1:00 p.m. Central European Time
|
The abstract is currently available on the ESMO website.
Please visit the following link to read the full abstract.
About Givastomig
Givastomig, also known as TJ-CD4B/ABL111, is a bispecific
antibody designed to bind to Claudin 18.2 (CLDN 18.2) as a tumor
engager and 4-1BB as a conditional T-Cell activator. It binds to
tumor cells expressing various levels of CLDN18.2, i.e., gastric
cancer and pancreatic cancer cells, and conditionally activates
intra-tumoral T cells at the tumor site through the 4-1BB arm.
Givastomig appears to effectively maintain a strong tumor binding
property and anti-tumor activity attributable to a synergistic
effect of both CLDN18.2 antibody and 4-1BB antibody while avoiding
or minimizing liver toxicity and systemic immunotoxicity commonly
seen with 4-1BB antibodies as a drug class. Being developed under
collaboration between I-Mab and ABL Bio, a clinical-stage
biotechnology company in South
Korea, givastomig is currently being investigated in a Phase
1 clinical study in the U.S. and China. In March
2022, the U.S. Food and Drug Administration (FDA) granted
Orphan Drug Designation for givastomig for the treatment of gastric
cancer, including cancer of the gastroesophageal junction.
About I-Mab
I-Mab (Nasdaq: IMAB) is a global biotechnology
company focused on bringing highly differentiated medicines to
patients around the world through the discovery, development, and
commercialization of novel immunotherapies and
biologics. I-Mab's innovative pipeline is driven by
internal R&D's Fast-to-Proof-of-Concept, Fast-to-Market
development strategies, and through global partnerships. For
more information, please
visit https://www.i-mabbiopharma.com and follow us
on LinkedIn, Twitter, and WeChat.
I-Mab Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
and other federal securities laws, including statements regarding
data from clinical studies of givastomig, the potential
implications of clinical data for patients, and I-Mab's advancement
of, and anticipated clinical development, regulatory milestones,
and commercialization of givastomig. Actual results may differ
materially from those indicated in the forward-looking statements
as a result of various important factors, including but not limited
to I-Mab's ability to demonstrate the safety and efficacy of its
drug candidates; the clinical results for its drug candidates,
which may not support further development or NDA/BLA approval; the
content and timing of decisions made by the relevant regulatory
authorities regarding regulatory approval of I-Mab's drug
candidates; I-Mab's ability to achieve commercial success for its
drug candidates, if approved; I-Mab's ability to obtain and
maintain protection of intellectual property for its technology and
drugs; I-Mab's reliance on third parties to conduct drug
development, manufacturing and other services; I-Mab's limited
operating history and I-Mab's ability to obtain additional funding
for operations and to complete the development and
commercialization of its drug candidates; and the impact of the
COVID-19 pandemic on the Company's clinical development, commercial
and other operations, as well as those risks more fully discussed
in the "Risk Factors" section in I-Mab's most recent annual report
on Form 20-F, as well as discussions of potential risks,
uncertainties, and other important factors in I-Mab's subsequent
filings with the US Securities and Exchange Commission. All
forward-looking statements are based on information currently
available to I-Mab, and I-Mab undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
may be required by law.
I-Mab Contacts
Investors
|
Media
|
Tyler Ehler
|
Gigi Feng
|
Senior Director,
Investor Relations
|
Chief Communications
Officer
|
IR@i-mabbiopharma.com
|
PR@i-mabbiopharma.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/i-mab-announces-phase-1-data-of-givastomig-at-esmo-2023-301957219.html
SOURCE I-Mab